Antisense Oligonucleotides Targeting XIAP Induce Apoptosis and Enhance Chemotherapeutic Activity against Human Lung Cancer Cells in Vitro and in Vivo

YanPing Hu, Gabriele Cherton-Horvat, Visia Dragowska, Stephen Baird, Robert G. Korneluk, Jon P. Durkin, Lawrence D. Mayer, 2 and Eric C. LaCasse 2,3


ABSTRACT

Activation of programmed cell death in cancer cells offers novel and potentially useful approaches to improving patient responses to conventional chemotherapy. X-linked inhibitor of apoptosis (XIAP), is the most potent member of the IAP gene family in terms of its ability to inhibit caspases and suppress apoptosis. In this study, we investigated the effect of XIAP down-regulation by antisense oligonucleotides (AS ODNs) on human non-small cell lung cancer (NIH-H460) growth in vitro and in vivo. In cultured H460 cells, G4 AS ODN was identified as the most potent compound. It down-regulated XIAP mRNA by 55% and protein levels up to 60% as determined by real-time quantitative reverse transcription-PCR and Western blotting, respectively, and induced 60% cell death. In contrast, the scrambled control ODN caused minimal XIAP loss and less than 10% cell death. Treatment with G4 AS ODN induced apoptosis as revealed by degradation of procaspase-3 and poly(ADP-ribose) polymerase proteins with significant nuclear DNA condensation and fragmentation. In addition, G4 AS ODNs sensitized H460 cells to the cytotoxic effects of doxorubicin, Taxol, vinorelbine, and etoposide. In animal models, administration of G4 AS ODN had significant sequence-specific inhibitory effects on H460 solid tumor establishment in a xenograft model. This antitumor activity was associated with an 85% down-regulation of XIAP protein in the tumors. In addition, the combination of 15 mg/kg G4 AS ODN with 5 mg/kg vinorelbine significantly delayed tumor establishment, more than either agent alone. These studies support the contention that XIAP is a viable target for cancer therapy in human non-small cell lung cancer.

INTRODUCTION

Lung cancer is one of the leading causes of cancer death in both men and women, despite recent advances made in early diagnosis and treatment. More than 75% of patients with NSCLC4 prove to be potential candidates for chemotherapy at some point during the course of their disease (1). However, chemotherapy provides rather poor response rates in NSCLC patients, with rare complete remissions. Clearly, new treatments must be developed to improve overall disease-free survival in NSCLC patients. Activation of programmed cell death in cancer cells can be induced by using AS ODNs that target antiapoptotic regulatory proteins and, consequently, has been identified as a potential targeted therapy to provide such improvements in cancer patients (2–4).

Apoptosis is directly involved in tumor cell death after treatment with chemotherapeutic agents and radiation and is a process that requires the activation of proteolytic enzymes termed caspases. Moreover, resistance to apoptosis is a hallmark of cancer, and failure to properly execute apoptosis through disabling mutations provides the cancer cells with an unwanted survival advantage (5, 6). Whether a cell undergoes apoptosis or continues through the cell cycle in response to potential apoptotic stimuli is under the control of a complex set of gene and protein interactions. Several potent endogenous proteins that inhibit apoptosis have been identified, including Bcl-2, and IAP families in mammalian cells. Certain members of the latter family directly inhibit terminal effector caspases, i.e., caspase 3 and caspase 7, engaged in the execution of cell death, as well as...
the key mitochondrial initiator caspase, caspase 9, important to
the mediation of cancer chemotherapy-induced cell death (7–
10). The IAPs are the only known endogenous caspase inhibi-
tors and, thus, play a central role in the regulation of apoptosis.

 XIAP is the most potent member of the IAP gene family in
terms of caspase inhibition and apoptosis suppression (7, 9, 10).
XIAP can be targeted for proteasome-dependent degradation on
proapoptotic stimuli because of its ubiquitin protein ligase ac-
tivity associated with its RING finger domain (16). This activity
also promotes ubiquitin-proteasomal degradation of IAP bind-
ing partners such as caspase-3 and enhances XIAP antipapoptotic
effect in Fas-induced cell death (17). Thus, XIAP regulation
through the proteasome is complex.

The IAPs have been postulated to contribute to the develop-
ment of some cancers, and a postulated causal chromosomal
translocation involving cIAP2/HIAP1 has been identified in
MALT lymphoma (18). A recent correlation between elevated
XIAP, poor prognosis, and short survival has been demonstrated
in patients with acute myelogenous leukemia (19). XIAP was
highly overexpressed in many tumor cell lines of the NCI (NIH)
panel (20). However, there has been little direct evidence of the
role XIAP plays in tumor establishment, growth, metastasis, and
resistance to chemotherapy in vivo.

To demonstrate the potential of XIAP as a valid and
attractive target for drug or AS therapy in H460 human NSCLC,
we investigated the molecular and pharmacological effects of
XIAP AS ODN treatment alone, and in combination with anti-
cancer drugs on H460 cells in vitro and in a tumor xenograft
model as a proof of principle. AS and control ODNs were
evaluated for XIAP mRNA and protein down-regulation, ability
to induce apoptosis alone, and sensitization of tumor cells to
chemotherapy agents. These studies indicate that XIAP down-
regulation represents an attractive target for improving the treat-
ment response of NSCLC.

MATERIALS AND METHODS

AS ODN Synthesis. A library of >96 nonoverlapping
chimeric ODNs, or MBOs, 19-mer AS ODNs was synthesized
as 2 × 2 MBO ODNs, composed of two flanking 2'-O-methyl
RNA residues at either end with PS linkages, and a central core
of 15 PO DNA residues. Each final product was desalted by
Sephadex G-25 chromatography (IDT Inc., Coralville, IO). This
chimeric wingmer configuration, and mix of PS and PO linkages
(referred to as 2 × 2 PS/PO), provided the minimum necessary
stability for experimentation although reducing nonspecific tox-
icity associated with PS residues and associated toxic by-prod-
ucts of the synthesis. This configuration also provided the most
cost-efficient chimeric ODN using expensive second-generation
AS chemistries. Fully phosphorothioated, nonchimeric, versions
of AS and control ODNs (PS-ODN) for in vivo and in vitro
studies were synthesized by Trilink Biotech (San Diego, CA)
and purified by RP-high-performance liquid chromatography.
PS-ODNs were used in animal studies because of their reduced
cost and their well-established track record and known toxicities,
and based on our previous experience with PS bcl-2 AS
ODNs in the same xenograft model (21).

Tumor Cell Lines and Animal Xenograft Model. The
human NSCLC cell line (large cell type) NCI-H460 (H460) was
obtained from the NCI tumor repository and was maintained in
RPMI 1640 supplemented with 10% FCS at 37°C in a humid-
ified atmosphere containing 5% CO₂. Cells were used in expo-
nential growth phase, up to a maximum of 25 in vitro passages.
Male SCID-RAG2 mice (7–9 weeks old, 23–26 g) were ob-
tained from British Columbia Cancer Agency Joint Animal
Facility breeding colony and were kept in aseptic environments.
A solid tumor model of H460 cells in SCID-RAG2 mice was
established by s.c. implantation of 1 × 10⁶ H460 cells on the
back of mice. All of the animal protocols were approved by the
British Columbia Cancer Agency Animal Welfare Committee.

Treatment of Cultured H460 Cells with AS ODNs and Anticancer Drugs. One day before in vitro transfection, H460
cells were plated in 6- or 96-well tissue culture plates. PS or
chimeric AS ODNs were delivered into cells with LFA 2000
(Life Technologies, Inc., Gaithersberg, MD) in the form of
liposome-ODN complexes. On a 4.5- or 6-h transfection,
the transfection medium was replaced by RPMI-10%FBS medium
without transfection reagent, and cells were incubated for an-
other 24 or 48 h before analysis.

Real-Time Quantitative RT-PCR. Total RNA from
H460 cells treated with liposome-ODN complex for 6 h was
immediately isolated using RNeasy mini-spin columns com-
bined with DNase treatment (Qiagen), and specific XIAP mRNA
was measured using a real-time quantitative RT-PCR method.
XIAP forward and reverse primers (used at 600 nM) and probe
(200 nM; 5'-GGTGATAAAAGTCAAGTCTTTCAGCTGT-3',
6FAM-CAACATGCTAAATGGTTCCAGGGTGCAAAT-
ATC-TAMRA, and 5'-TCAGTATGTCATACGACACTCCT-
CTCAA-3') were designed to span exon 3–4 and 4–5 junctions.
One of the primers, as well as the probe, was designed to
overlap an intron-exon boundary to block detection of any
possible genomic DNA contamination. The RNA was reverse-
transcribed and PCR was amplified using the Taqman EZ RT-
PCR kit (PE/Appplied Biosystems Inc.) in the ABI prism 7700
Sequence Detection System (PE/ABI). The thermal cycling
conditions for the RT step were 50°C for 2 min, 60°C for 30
min, and 95°C for 5 min, followed by 45 cycles of PCR (at 94°C
for 20 s and 60°C for 1 min/cycle). The XIAP mRNA level of
each sample was calculated relative to untreated control cells.
XIAP mRNA levels were determined by the cycle threshold
method using a threshold of 30× the baseline SD, and XIAP
levels were normalized for GAPDH mRNA content, using PE/
ABI supplied primers and probe.

Western Blot Analysis. For in vitro experiments, cells
were treated with liposome-ODN complexes for 4.5 h and were
incubated for another 24 h in complete medium without trans-
fection reagent and ODN. For in vivo ODN treatments, see
below (Tumor and Tissue Processing). The cells or tumor tissue
were lysed with ice-cold lysis buffer (50 mM Tris, 150 mM NaCl,
2.5 mM EDTA, 0.1% SDS, 0.5% sodium deoxycholate, 1%
NP40, and 0.02% sodium azide) containing protease inhibitors (Complete-Mini protease inhibitor tablets; Boehringer Mannheim GmbH, Mannheim, Germany). After incubation for 30 min on ice, samples were centrifuged at 10,000 rpm for 15 min, and were stored at −20°C. Protein content in the lysed extracts was determined using a detergent-compatible Bio-Rad assay (Bio-Rad Labs, Hercules, CA). Equal amounts of protein (40 μg/lane) were subjected to, and separated in, 12% SDS-polyacrylamide gels or 4–15% gradient SDS-polyacrylamide pre-made gels (Bio-Rad) and were transferred to nitrocellulose membranes (Mandel, Guelph, Canada). The primary antibodies against XIAP (rabbit polyclonal; Aegera Oncology Inc., Ottawa, Ontario, Canada), Bcl-2 (mouse monoclonal; DAKO, Glostrup, Denmark), Bax (rabbit polyclonal; Sigma, St. Louis, MO), caspase-3 and PARP (rabbit and mouse monoclonal, respectively; BD PharMingen, San Diego, CA) were obtained and used. The mouse antihuman β-actin monoclonal antibody was purchased from Sigma. The secondary antibody used was the appropriate horseradish-conjugated antimouse or antirabbit IgG (Promega, Madison, WI). Proteins were detected by enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, England) and were visualized after exposure to Kodak autoradiography film. Scanning densitometry (Molecular Dynamics, Sunnyvale, CA) was performed to quantify band intensities by volume/area integration. The amount of XIAP, caspase-3, Bcl-2, and Bax in cells was normalized to their respective lane β-actin levels.

Measurement of Cell Viability. Growth inhibition of H460 cells was determined by the colorimetric MTT cell viability/proliferation assay. In brief, cells were treated with liposome-ODN complex for 4.5 h, then were incubated for another 48 h at 37°C in the medium without transfection reagent or ODN in the presence or absence of anticancer drugs. MTT (25 μg/well) was added to each well and plates were incubated for 3.0 h at 37°C. The colored formazan product was then dissolved using 200 μl of DMSO. Plates were read using the microtiter plate reader (Dynex Technologies Inc., Chantilly, VA) at a wavelength of 570 nm. The percentage of dead (or growth-inhibited) cells treated with the different concentrations of ODNs was normalized to untreated controls. All of the assays were performed in triplicate.

CalcuSyn software (Biosoft, Ferguson, MO) was used to analyze data from MTT assay of cells exposed to G4 AS ODN alone or in combination with anticancer drugs to determine additive or synergistic effects. The CI equation in CalcuSyn is based on the multiple drug-effect equation of Chou and Talalay (see CalcuSyn manual) (40) and defines synergism as a more-than-expected activity effect and antagonist as a less-than-expected additive effect. Chou and Talalay defined a CI of <1, 1, and >1 as synergism, additive, and antagonism, respectively.

Apoptotic Flow Cytometric Assays. Cells were treated with liposome-ODN-complex for 4.5 h and were incubated for another 48 h in the medium without transfection reagent at 37°C. Cells were harvested, washed twice with sample buffer (0.5% glucose in PBS without Ca2+ or Mg2+), and were fixed in cold 70% ethanol at 4°C for at least 18 h. Samples were centrifuged at 3000 rpm for 10 min and were resuspended in sample buffer containing 50 μg/ml PI and 400 units/ml RNase A. Samples were incubated for 30 min at room temperature and for 30 min on ice, followed by flow cytometry analysis. EXPO Software (Applied Cytometry Systems) was used to generate histograms, which were used to determine the cell cycle phase distribution after debris exclusion. The sub-G1-G2 cell fraction was considered as representative of apoptotic cells.

Nuclear Morphology. Cells were treated with liposome-ODN complexes for 4.5 h and were incubated for another 48 h at 37°C in the medium without transfection reagent or ODN. Cells were harvested and stained with 0.1 μg/ml DAPI for 30 min at room temperature. Cells were placed on a glass slide, were cytops and were viewed with a Leica microscope (Germany) and ×40 objective lens under UV fluorescent illumination. Digital images were captured using Imagedatabase V. 4.01 Software (Leica, Germany).

In Vivo Antitumor Establishment Activity. Efficacy experiments were conducted in male SCID/RAG2 immunodeficient mice bearing H460 tumors (six mice/group). Treatments were commenced on day 3 after tumor inoculation. Saline (vehicle controls), G4 AS, or SC control ODNs were administered i.p. daily at 5 or 15 mg/kg for five doses per week over a 3-week regimen. VNB (5 or 10 mg/kg) was administered i.v. on days 3, 7, 11, and 17 after cell inoculation via a lateral tail vein, either alone or in combination with ODNs, which were administered i.p. When ODNs were administered in combination with VNB, the i.v. drug treatment was staggered 4 h after i.p. ODN treatment.

Mice were observed daily and body weight measurements and signs of stress (e.g., lethargy, ruffled coat, and ataxia) were used to detect possible toxicities. Animals with ulcerated tumors (<1 cm3) were euthanized. Electronic caliper (Mitutoyo Corp., Kawasaki, Japan) measurements of tumors were converted into mean tumor size (cm3) using the formula: \( \frac{1}{2} \times \text{length (cm)} \times \text{width (cm)} \). An average tumor size per mouse was used to calculate the group mean tumor size ± SE (n = 6 mice) from at least two independent experiments.

Tumor and Tissue Processing. Mouse tumors were collected on day 21 post-tumor-inoculation and treatment. One portion of tumor tissue was fixed in formalin. Paraffin-embedded tissues were sectioned and were subjected to gross histopathology using H&E staining. The other tumor portion was homogenized in lysis buffer for Western Blot analysis (see above).

Statistical Analyses. The Student's t test was used to measure statistical significance between two treatment groups. Multiple comparisons were done using one-way ANOVA and post hoc test that compared different treatment groups by the Shellé test criteria (Statistica release 4.5; Soft Inc., Tulsa, OK). Data were considered significant for a P of <0.05.

RESULTS

Screen Strategies for Identifying AS ODNs with Optimal Effects on XIAP Expression. To specifically down-regulate the expression of XIAP mRNA in tumor cells, we designed a series of >100 19-mer ODN targeting various sites of XIAP mRNA. To initially test the efficacy of these ODNs in suppressing XIAP mRNA and protein levels, T24 human bladder carcinoma cells were used. This cell line was chosen for the primary screen because of its (a) ease of growth and mainte-
The Oligonucleotide Sequence and their target site on XIAP mRNA

<table>
<thead>
<tr>
<th>Oligonucleotide</th>
<th>Sequence*</th>
<th>Position (nucleotide no.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F3 AS</td>
<td>ATCTTCTCTTTGGAAATAGG</td>
<td>17–35</td>
</tr>
<tr>
<td>F3 RP</td>
<td>GGATAAAAAGTCTCTCTCTA</td>
<td>17–35</td>
</tr>
<tr>
<td>G4 AS</td>
<td>GCGTAGCTCCATATGGCC</td>
<td>251–269</td>
</tr>
<tr>
<td>G4 SC</td>
<td>GCCTTCTTGGACACCTGA</td>
<td>354–372</td>
</tr>
<tr>
<td>C5 AS</td>
<td>ACCATTTGGAACCGAA</td>
<td>470–488</td>
</tr>
<tr>
<td>C5 RP</td>
<td>AAGCCCAAGTCTCTACAA</td>
<td>166–184</td>
</tr>
<tr>
<td>AB6 AS</td>
<td>GGGTTCTCCCCGGTATG</td>
<td>719–737</td>
</tr>
<tr>
<td>AB6 RP</td>
<td>GGTATATGCCGCTCTTTG</td>
<td>719–737</td>
</tr>
<tr>
<td>DE4 AS</td>
<td>GGTACTTCTCCTTACAGTA</td>
<td>166–184</td>
</tr>
<tr>
<td>DE4 RP</td>
<td>ATGACCACTTCTCTATG</td>
<td>166–184</td>
</tr>
<tr>
<td>D7 AS</td>
<td>GATTCACTTCTGAATATTAA</td>
<td>166–184</td>
</tr>
<tr>
<td>D7 RP</td>
<td>AATTATAGGTACCTTGA</td>
<td>166–184</td>
</tr>
</tbody>
</table>

*Chimeric (2 × 2 PS/PO) and fully phosphorothioated AS ODNs (PS-ODN) have the same sequence, with the exception of the substitution of a uracyl base (U) for a thymidine base (T) in the RNA flanking regions (underlined sequences). Differences in chemical structures were described in “Materials and Methods.” Corresponding control oligonucleotides are shown either as RP or SC sequences.

Table 1 Sequences of AS ODNs and their target site on XIAP mRNA

Fig. 1 AS-mediated specific down-regulation of XIAP mRNA in H460 cells in vitro. XIAP mRNA levels in H460 cells treated with LFA 2000 alone (LFA) or LFA with 1.2 μM of XIAP AS ODN F3, G4, C5, AB6, DE4, or D7 and their RP or SC ODN control. Real-time RT-PCR quantification of the relative amount of XIAP mRNA was performed at 6 h of transfection. All of the data are presented as the mean ± SD of triplicates from a representative experiment. The level of XIAP mRNA in untreated cells (Control) maintained under identical experimental conditions was assigned a value of 1.
XIAP AS Effects against Human Lung Cancer Cells

2830

XIAP Expression in H460 Tumors Treated with G4 AS ODN. To correlate G4 AS ODN tumor antitumor establishment effects with XIAP protein expression, we examined the changes in XIAP expression in solid tumors of mice treated with 15 mg/kg of G4 AS and SC ODNs. At day 21 post-tumor-inoculation (Fig. 6A), tumors were harvested, and lysates from tumor homogenates were analyzed for XIAP expression using Western blotting. As shown in Fig. 5B, cells treated with G4 AS ODNs displayed significant down-regulation of XIAP protein levels compared to untreated control cells. In contrast, few cells treated with G4 SC ODNs displayed partial down-regulation of XIAP expression.

Fig. 2 AS-mediated specific down-regulation of XIAP protein in H460 cells in vitro. XIAP protein levels in H460 cells, which were treated with LFA 2000 alone (LFA) or LFA plus 1.2 μM of XIAP AS ODN F3, G4, or C5 and their respective ODN controls (RP or SC) for 4.5 h and incubated for another 24 h in complete medium without transfection reagent and ODN. XIAP protein levels were analyzed by Western blotting (A), and the amount of protein was quantitated by densitometry (B). XIAP levels were normalized to cellular actin levels (n = 3), and were compared with untreated control (CNT) levels. kDa, Mr in thousands.

Fig. 3 Induction of Apoptosis by AS ODNs. To investigate whether down-regulation of XIAP expression has the potential to sensitize H460 cells to chemotherapy, a combination treatment of G4 AS ODNs and DOX, Taxol, VNB, and Etop was performed. Fig. 3B demonstrates that H460 cells treated with 0.4 μM G4 AS ODN, 0.5 μM DOX, 10 μM Taxol, 10 μM VNB, or 1.0 μM Etop induced ∼14.3, 17.5, 15.6, 11.2, or 9.6% of cell death, respectively, compared with untreated control cells. In comparison, the combination treatments of 0.4 μM G4 AS ODN with 0.5 μM DOX, or 10 μM Taxol, or 10 μM VNB, or 1.0 μM Etop resulted in ∼40.5, 37.5, 36.4, or 33.3% cell deaths, respectively. These data indicated that combination treatments were more effective at inducing cytotoxic effect in tumor cells, compared with treatment with either G4 AS ODN or anticancer drug alone. Combinations of multiple ratios of G4 AS ODN and anticancer drugs were analyzed for drug synergy using Calculate software. The results of this analysis suggested that synergistic cytotoxic effects occurred for combinations of G4 AS ODN with Taxol (CI = 0.60–0.80), VNB (CI = 0.78–1.05), and Etop (CI = 0.50–0.55), as indicated by the CI values of ≤1.0 (CI plots not shown), see “Materials and Methods” for CI analysis.

Antitumor Efficacy of G4 AS ODNS against H460 Tumor Xenografts. We tested the antitumor establishment effects of G4 AS ODN in SCID/RAG2 mice bearing xenografts of H460 human non-small cell lung tumors implanted s.c. Saline-treated control tumors grew reproducibly to a size of 0.75 cm³ within ∼24 days (Fig. 6A). ODN treatments were initiated 3 days after tumor cell inoculation. G4 AS ODNS (5–15 mg/kg) were administered using a treatment schedule of i.p. injections given on days 3–7, 10–14, and 17–21 (once a day), based on the persistent reduction of XIAP protein levels by 62% after 24 h posttransfection in vitro study. Treatment with G4 AS ODNS inhibited tumor growth in a dose-dependent fashion; specifically, on day 24, mean tumor sizes were 0.75, 0.45, and 0.29 cm³ in the control and the 5-mg/kg and 15-mg/kg AS ODN treatment groups, respectively (Fig. 6A). In contrast, administration of G4 SC ODN at 15 mg/kg as a control ODN provided no therapeutic activity (Fig. 6A). Additionally, none of the mice treated with ODNs displayed significant signs of toxicities, and both doses of ODNs were well tolerated. Hence, to have the best therapeutic effects, a dose of 15 mg/kg/day (5 days on, 2 days off) was selected for the future combination treatment regimen with anticancer drugs.
nates were used for Western blot analysis. XIAP and β-actin antibodies against the human protein were used, allowing for determination of human XIAP levels obtained from tumor cell specimens without contamination from XIAP derived from mouse cells. As shown in Fig. 6, B and C, XIAP protein levels in tumors treated with G4 AS ODNs were significantly reduced to ~15% of expression levels in control tumors (P < 0.005). In contrast, the XIAP protein in tumors treated with G4 SC ODN were decreased to only 76% of expression levels in control tumors, and the change was not statistically significant. XIAP protein in the group treated with G4 AS ODNs was significantly lower than in its ODN control group (P < 0.05). These results indicated that inhibition of H460 solid tumor establishment by G4 AS ODNs was correlated with the down-regulation of XIAP protein expression.

Histopathology of Tumor Specimens. To evaluate whether G4 AS ODN administration results in direct tumor cell death, we examined the morphological changes (H&E staining) of tumors after treatment (Fig. 7). Experiments were performed in parallel with the Western blot studies of tumor samples to correlate XIAP protein and tumor cell death (Fig. 6B versus Fig. 7). At day 21 post-tumor-inoculation, tumors treated with 15 mg/kg of G4 AS, or SC ODN and saline were excised, sectioned, and stained with H&E. The results demonstrated that tumors given G4 AS treatment showed a large increase in the number of dead cells, identified morphologically by their amorphous shape and condensed nuclear material, reflecting a large percentage of cell death (Fig. 7). The enlarged insert is an amplification of the small square area, which shows morphological changes of dying tumors cells treated with G4 AS (Fig. 7). In contrast, tumors from control mice or SC ODN-treated controls were composed of densely packed live tumor cells with a very small number of dead cells (Fig. 7).

Combined Treatment of G4 AS ODN with VNB. To evaluate whether combined treatments of G4 AS ODN and a chemotherapeutic agent used for lung cancer treatment, VNB, in H460 tumors may result in any cooperative effects, we compared the therapeutic efficacy of VNB in the presence and absence of G4 AS or SC ODNs. Treatment regimens were initiated on days 3 after cell inoculations. Fig. 8A presents the in vivo efficacy results for 5-mg/kg and 10-mg/kg doses of VNB given to H460 tumor-bearing mice and compared with saline controls. The two regimens induced significant antitumor establishment effects in a dose-dependent manner (Fig. 8A) without
showing significant signs of undesirable toxicity (i.e., body weight loss).

When G4 AS ODN (15 mg/kg) was combined with VNB (5 mg/kg) for the treatment of H460 tumors, an even more pronounced delay of H460 tumor establishment was observed compared with either treatment administered alone (Fig. 8B versus Fig. 6A and 8A). These mice did not show any significant signs of overt toxicity. Moreover, we compared the mean tumor sizes in mice treated with 5 mg/kg VNB in the presence or absence of G4 AS or SC ODNs on day 29 (Fig. 8, A and B). The tumor sizes in the group of combined VNB and G4 AS ODNs were $0.22 \pm 0.03$ cm$^3$, which was significantly ($P < 0.01$) smaller than $0.59 \pm 0.04$ and $0.48 \pm 0.05$ cm$^3$ in the treated groups of 5 mg/kg VNB alone and combination of VNB with G4 SC ODNs, respectively. However, with all of the treatments, tumor growth persisted despite concurrent G4 AS ODN and/or VNB treatment after an initial response.

**DISCUSSION**

Modulation of gene expression by AS ODNs is a promising therapeutic approach because of its target specificity and potential applicability to any sequenced gene (22, 23). Appropriately designed AS ODNs can achieve anticancer gene-targeted therapy based on reducing the level of a putative oncoprotein. Synthetic AS ODNs bind RNA molecules in a sequence-specific manner and either directly impair interaction with factors in the cytoplasm that are required for translation or recruit endogenous RNaseH to cleave the RNA backbone (24). Regardless of the exact mechanism, AS ODNs represent a potential drug therapy...
In the present study, we examined a series of 19-mer AS ODNs targeting various regions of XIAP mRNA. The G4 AS ODN was identified as one of the most efficient down-regulators of XIAP mRNA and protein levels. G4 AS ODN was designed to hybridize to sequences located in the region encoding the baculovirus IAP repeat (BIR) domain. A BLASTN search of a database containing all of the sequences of GenBank was performed; this revealed a lack of similar complementarity of the AS ODN to human genes other than XIAP (birc4 gene symbol). G4 AS ODN down-regulated 60% of XIAP mRNA and protein in vivo at a concentration of 1.2 μM. At the same time, G4 AS ODN, indeed, induced a strong antistress expression in H460 human NSCLC cells in vivo and in vitro. Similar results were obtained with MDA-MB-435/LCC6 human breast cancer cells and T24 human bladder carcinoma cells (data not shown).

It is known that XIAP directly binds to, and inhibits, active caspase-3, as well as blocking the processing and activation of pro-caspase-3, recognized as the key downstream component of different major apoptotic pathways (28–30). Our data indicated that XIAP AS treatments led to the activation of caspase-3 as well as to the degradation of the caspase-3 substrate, PARP, which resulted in the morphological changes that are hallmarks of apoptosis (e.g., nuclear DNA condensation and fragmentation) and, finally, cell death. This observation is in agreement with the findings of others that, after adenoviral AS expression, XIAP down-regulation activated caspase-3 and induced apoptosis in the wild-type p53-chemoresistant cancer cells (31). Treatment of mature bone marrow-derived macrophages from mice with XIAP AS ODNs partly abolished their resistance to apoptosis (32). Using G4 AS ODN in combination with DOX, Taxol, VNB, and Etop, we provide evidence here that down-regulation of XIAP expression sensitizes cancer cells to death induction by a wide range of chemotherapeutic agents.

We did not examine, in this report, the effects of the AS ODNs on other reported activities of XIAP, such as E3 ubiquitin ligase activity or signal transduction effects on TGF-β, or JNK pathways, because the physiological relevance of these secondary activities is unclear. However, all of the reported secondary activities that are attributed to XIAP do support the ant apoptotic effects of XIAP, with the only exception being the E3 ligase activity, which can remove IAP antagonists and caspases (antiapoptotic effects) but also lead to the degradation of the IAPs themselves (proapoptotic effects) in a complex regulatory mechanism that is not fully understood.

To date, studies on biological effects of XIAP AS ODNs in vivo had not been reported. In the studies described here, we evaluated the in vivo activity of XIAP G4 AS ODNs in the xenograft solid-tumor model of H460 human NSCLC. This model was chosen to assess whether XIAP manipulation may affect tumor establishment and chemosensitivity in a human tumor cell line exhibiting high inherent XIAP expression. The data presented here are the first, to our knowledge, to demonstrate that daily i.p. G4 AS ODN treatment (5 days on, 2 days off) administered over 3 weeks was capable of achieving significant XIAP down-regulation (85% XIAP protein reduction). This was associated with antitumor establishment activity in this animal tumor model at a dose of 15 mg/kg per injection per day (5 days on, 2 days off). This effect was specific for the G4 AS ODN sequence, because there was no activity associated with

to reduce target protein levels and activity, because of overexpression of a specific disease-associated protein.

Overexpression of XIAP in tumor cells provides a strong inhibitory effect on cell death induced by a variety of apoptotic stimuli and induces resistance to chemotherapy (14). This has generated a great deal of interest for therapeutic intervention aimed at inhibiting the activity of, or reducing, the expression levels of XIAP, by means such as using XIAP AS ODNs. Manipulations aimed at shifting the balance of apoptosis control in favor of cell death may lead directly to tumor cell death and/or sensitization of tumor cells to chemotherapeutic agents. The AS ODNs targeting Bcl-2, another antiapoptosis protein, have been successfully used in this fashion against cancers in human xenograft tumor models and cancer patients (2, 21, 25–27). Therefore, using XIAP AS ODNs alone and in combination with anticancer drugs to treat human NSCLC seemed to be another viable therapeutic approach for investigation.
the control G4 SC ODNs. Furthermore, the histology of the AS
ODN-treated tumors revealed significant induction of cell death
and indicated that the decrease of tumor size was caused by an
efficient tumor cell death (Figs. 6A and 7).

Although some AS ODNs containing unmethylated CpG
motifs within the ODN sequence have been shown to be potent
immune stimulators (33, 34), there is no CpG motif in our G4
AS ODN sequence. This strengthens the argument that the
antitumor efficacy of the G4 AS ODNs observed here is a
specific AS effect resulting from the sequence itself rather than
an immunological effect.

XIAP is ubiquitously expressed in all normal tissues (35–37),
and the function of XIAP in normal cells is presumably to
suppress inadvertent activation of the caspase cascade. In addi-
tion, XIAP may provide a threshold of apoptotic resistance in
the normal cell, allowing a possible recovery phase when toxic
insults occur, but once this threshold is surpassed, the cell is
committed to a point of no return and fully commits to death.

Harlin et al. (38) developed a XIAP-deficient mouse strain and
found that the XIAP-deficient mice were born at the expected
Mendelian frequency and had no obvious physical or histological
defects, as well as having normal life spans. This suggests the
possibility of no deleterious effects in normal cells treated with
G4 AS ODNs. We did not detect any overt toxicity of daily
15-mg/kg i.p. injections of G4 AS ODNs in the mouse, in terms
of gross histological examination and organ and total body

Fig. 7 In vivo AS effects on tumor histopathology. Histopathology of H460 tumors implanted in SCID/RAG2 mice after 15-mg/kg systemic dosing of XIAP G4 AS ODN (G4AS), G4 SC ODN (G4SC) treatment, and untreated control (CNT) for 21 days. Tumor sections were stained with H&E; the enlarged insert is an amplification of the small square area. Representative tumor pictographs are shown (×40 objective). Internal scale markers, 100 μm.

Fig. 8 Increased in vivo efficacy of VNB in combination with XIAP AS ODNs. Antitumor establishment efficacy of VNB with or without XIAP G4 AS ODN or G4 SC ODN against H460 tumors xenografts in SCID/RAG2 mice. The tumor inoculation, treatment schedules, and tumor measurement were described in “Materials and Methods.” A, antiestablishment activity of single agents. Antiestablishment efficacy of VNB (5 or 10 mg/kg) against H460 tumors xenografts in SCID/RAG2 mice. VNB 5 mg/kg or 10 mg/kg versus control, P < 0.0001 on day 24. B, antiestablishment activity of VNB and AS combination. Antiestablishment efficacy of VNB (5 mg/kg) or G4 AS ODN (15 mg/kg) alone, and VNB combined with G4 AS ODN or G4 SC ODN (15 mg/kg) against H460 tumors xenografts in SCID/RAG2 mice. VNB (5 mg/kg) + G4 AS ODN (15 mg/kg) versus VNB (5 mg/kg) or VNB + G4 SC ODN, P < 0.01, on day 29. All of the data are expressed as means ± SE (n = 6 mice/group). A and B, as well as Fig. 6A, are from the same experiment, and are represented separately for the sake of clarity. Error bars (omitted in B) for VNB 5 mg/kg and G4 AS 15 mg/kg are indicated in A and in Fig. 6A, respectively.
weights (data not shown). Because there is a single base difference in the 19-mer AS ODN sequence between human and murine XIAP, direct correlations between murine and human toxicity may not be appropriate.

In addition to the direct antitumor activity of G4 AS ODNs against human lung cancer xenografts, we have demonstrated that XIAP down-regulation produced by G4 AS ODNs enhanced the anticaner activity of VNB, a Vinca alkaloid, which works by interfering with microtubule assembly. VNB is approved for use as a single agent for patients with stage IV NSCLC disease and in combination with cisplatin for patients with stage III NSCLC. The combination treatment of G4 AS ODN and VNB significantly reduced the rate of tumor establishment and increased antitumor activity over that obtained with G4 AS ODN or VNB alone against human lung cancer xenografts. These results suggest that the combination of G4 AS ODN and VNB might sensitize patients with late-stage NSCLC to chemotherapy.

Planned future studies will address the efficacy of XIAP AS ODNs, alone or in combination with cytotoxic drugs, to induce regression in more clinically relevant xenograft models. The studies reported here demonstrate proof of concept that XIAP AS ODNs have antitumor establishment effects in a xenograft model, and that, like most other AS molecules targeted at cancer cells, is expected to show only true AS-mediated regression in combination with cytotoxic agents. Although data are presented here from a NSCLC xenograft model, it is not known whether NSCLC represents a valid indication for XIAP AS. This will not be known until XIAP AS is tested in the clinic.

In summary, the studies presented here are the first to demonstrate the therapeutic efficacy of a cytotoxic agent VNB in a human NSCLC xenograft model. This information may enhance our ability to apply novel therapies targeting apoptosis regulation with conventional cytotoxic agents in a manner that will significantly improve the management of cancer with chemotherapy.

ACKNOWLEDGMENTS

We thank Dana Masin, Rebecca Ng, Sophia Tan, and Natasha Harasym for their excellent technical assistance and efforts in performing the in vivo studies, as well as Lynn Kelly, Martine St-Jean, and Charles Lefebvre for AS ODNs screening studies.

REFERENCES

Antisense Oligonucleotides Targeting XIAP Induce Apoptosis and Enhance Chemotherapeutic Activity against Human Lung Cancer Cells \textit{in Vitro} and \textit{in Vivo}

YanPing Hu, Gabriele Cherton-Horvat, Visia Dragowska, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/9/7/2826

Cited articles
This article cites 38 articles, 20 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/9/7/2826.full#ref-list-1

Citing articles
This article has been cited by 21 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/9/7/2826.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.